Abstract:Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening and interstitial lung disease with the median survival of only 3-5 years. However, due to the unclear etiology and problems in accurate diagnosis, up to now only two drugs were approved by FDA for the treatment of IPF and their outcome responses are limited. Numerous studies have shown that TGF-beta is the most important cytokine in the development of pulmonary fibrosis and plays a role through its downstream signaling molecule TGF-binding receptor Smads protein. In this paper, compounds bearing 2(1H)-quinolone scaffold were designed and their anti-fibrosis effects were evaluated. Of these compounds, 20f was identified as the most active one and could inhibit TGF-beta-induced collagen deposition of NRK-49F cells and mouse fibroblasts migration with comparable activity and lower cytotoxicity than nintedanib in vitro. Further mechanism studies indicated that 20f reduced the expression of fibrogenic phenotypic protein alpha-SMA and collagen I by inhibiting the TGF-beta/Smad dependent pathways and ERK1/2 and p38 pathways. Moreover, compared with the nintedanib, 20f (100 mg/kg/day, p.o) more effectively alleviated collagen deposition in lung tissue and delayed the destruction of lung tissue structure both in bleomycin-induced prevention and treatment mice pulmonary fibrosis models. The immunohistochemical experiments further showed that 20f could block the expression level of phosphorylated Smad3 in the lung tissue cells, which resulted in its anti-fibrosis effects in vivo. In addition, 20f demonstrated good bioavailability (F = 41.55% vs 12%, compare with nintedanib) and an appropriate elimination half-life (T-1/2 = 3.5 h), suggesting that 20f may be a potential drug candidate for the treatment of pulmonary fibrosis. (C) 2020 Published by Elsevier Masson SAS.

Synthesis and Discovery of New Compounds Bearing Coumarin Scaffold for the Treatment of Pulmonary Fibrosis.

Design, Synthesis and Discovery of 2(1H)-Quinolone Derivatives for the Treatment of Pulmonary Fibrosis Through Inhibition of TGF-β/smad Dependent and Independent Pathway.

Exophilone, a Tetrahydrocarbazol-1-one Analogue with Anti-Pulmonary Fibrosis Activity from the Deep-Sea Fungus Exophiala Oligosperma MCCC 3A01264

Influence of the extract of Compound Formula Rosin and Bletilla Table in Bleomycin induced pulmonary fibrosis in mice

Synthesis and Biological Evaluation of 4-Oxoquinoline-3-carboxamides Derivatives As Potent Anti-Fibrosis Agents

Design, synthesis and biological evaluation studies of novel anti-fibrosis agents bearing sulfoxide moiety

Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-β1 pathway.

One-pot synthesis and pharmacological evaluation of new quinoline/pyrimido-diazepines as pulmonary antifibrotic agents

β-Carboline Alkaloids From the Deep-Sea Fungus Trichoderma sp. MCCC 3A01244 as a New Type of Anti-pulmonary Fibrosis Agent That Inhibits TGF-β/Smad Signaling Pathway

Synthesis of Novel 2-(Pyridin-2-yl) Pyrimidine Derivatives and Study of Their Anti-Fibrosis Activity

Discovery of a Selective and Potent Inhibitor of C-Jun N-terminal Kinase 1 with Anti-Pulmonary Fibrosis Effect

Design and Synthesis of Matrine Derivatives as Novel Anti-Pulmonary Fibrotic Agents via Repression of the TGFβ/Smad Pathway.

Structural Optimization of Moracin M As Novel Selective Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis

Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis

Discovery of a Novel Pleuromutilin Derivative As Anti-Ipf Lead Compound Via High-Throughput Assay

Design, synthesis, and evaluation of pirfenidone-NSAIDs conjugates for the treatment of idiopathic pulmonary fibrosis

Monomeric Compounds from Traditional Chinese Medicine: New Hopes for Drug Discovery in Pulmonary Fibrosis.

Synthesis and Evaluation of New Pirfenidone Derivatives As Anti-Fibrosis Agents

Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways

Synthesis and structure-activity relationships of pirfenidone derivatives as anti-fibrosis agents in vitro

Design, synthesis and anti-fibrosis activity study of N₁-substituted phenylhydroquinolinone derivatives.